Clinical implications of minimal residual disease monitoring in multiple myeloma.
Measuring minimal disease residual in multiple myeloma guides treatment decisions, helping doctors personalize care intensity based on what cancer cells remain.
This review synthesizes current evidence on MRD monitoring in multiple myeloma, covering NGS and NGF methodologies, major clinical trial data across newly diagnosed and relapsed settings, and the emerging MRD-adapted therapy paradigm. MRD negativity has emerged as a critical decision-making tool to personalize treatment intensity, though optimal testing timing and routine integration remain open questions.
What the study was
- Study design
- Narrative review
- Population
- Multiple myeloma patients (newly diagnosed and relapsed/refractory)
- Category
- Diagnostics
- Maturity
- Validated
- Journal
- Int J Hematol
Why it surfaced
Solid MRD review in MM from Int J Hematol. No new primary data; covers a well-established but rapidly evolving space. Useful pipeline context for downstream MM-related queries.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.